Squarepoint
RKDA icon

Squarepoint’s Arcadia Biosciences RKDA Stock Holding History

Squarepoint’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-486
Closed -$27K – 3291
2022
Q1 		$27K Buy
+486
New +$23.2K ﹤0.01% 2703
2019
Q4 		– Sell
-661
Closed -$124K – 2748
2019
Q3 		$124K Buy
+661
New +$127K ﹤0.01% 2162
2018
Q2 		– Sell
-415
Closed -$399K – 2002
2018
Q1 		$399K Buy
+415
New +$186K 0.01% 1179

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Squarepoint's RKDA Position: Q2 2022 in Review

Squarepoint sold out of Arcadia Biosciences (RKDA) in Q2 2022, closing a stake of 486 shares — an estimated $27K sold.

Squarepoint first reported a position in RKDA in Q1 2018 and held it in 3 quarters. The position peaked at $399K in Q1 2018. 22 funds tracked by Wall St. Rank hold RKDA as of Q2 2022.

  • Squarepoint reported no remaining Arcadia Biosciences position as of Q2 2022 after selling out during the quarter.
  • Squarepoint sold 486 Arcadia Biosciences shares in Q2 2022, an estimated $27K.
  • Squarepoint first reported a position in Arcadia Biosciences in Q1 2018 and held it in 3 quarters.
  • Squarepoint's Arcadia Biosciences position peaked at $399K in Q1 2018.
  • 22 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2022.

Based on Squarepoint's 13F filing for Q2 2022, filed 15 Aug 2022.